Industries de la santé
28 Mars 2017
Pharmaceutical companies hoping to effectively compete in the tauopathies space, which is yet to see its first drug hit the market, are adopting a broad range of strategies including entering into licensing agreements and partnerships for the co-development of products, and pursuing multiple indications and drug candidates, according to research and consulting firm GlobalData. |The...
Plus d'articles...
- Exercice 2016 historique pour VEXIM : Résultat net bénéficiaire et génération de trésorerie d'exploitation positive au 2ème Semestre
- Indivior’s new schizophrenia drug may improve patient compliance
- Immune thrombocytopenia market will see minimal growth to $985 million by 2025
- Onxeo présentera des données scientifiques sur ses 3 actifs clés en oncologie lors du congrès annuel de l'ACCR